Immunomedics, Inc.'s Results From Phase II Trial of Epratuzumab and Rituximab as Initial Treatment for Follicular Lymphoma Reported in an Oral Presentation at American Society of Hematology

ORLANDO, Fla., Dec. 6, 2010 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that combination therapy with epratuzumab and rituximab was effective, with durable complete responses in one-third of evaluable patients, and was very well tolerated by patients with previously untreated follicular lymphoma (FL).